World's Best Scientists 2026 revealed!
Patrick Marcellin

Patrick Marcellin

Award Badge
Medicine
France
2023

D-Index & Metrics

Medicine

D-Index
146
Citations
92102
World Ranking
1328
National Ranking
30

Research.com Recognitions

  • 2023 - Research.com Medicine in France Leader Award

Overview

Patrick Marcellin is affiliated with Université Paris Cité in France and focuses primarily on medical research. Their publication record includes 81 works, largely concentrated in medicine with a strong emphasis on epidemiology and hepatology. Subfields of study also cover infectious diseases, surgery, and health information management.

The scientist's research addresses a range of topics within liver disease and viral infections. Major areas of work include:

  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Liver Disease Diagnosis and Treatment
  • Hepatitis Viruses Studies and Epidemiology
  • HIV/AIDS drug development and treatment
  • Liver Disease and Transplantation
  • Cholangiocarcinoma and Gallbladder Cancer Studies

Patrick Marcellin has published frequently in several scientific journals. Notable publication venues are:

  • Journal of Hepatology
  • JHEP Reports
  • Liver International
  • UNC Libraries
  • Gastroenterology

Recent papers reflect ongoing investigation into viral hepatitis and liver health. Selected publications include:

  • "Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety," 2023, The American Journal of Gastroenterology
  • "Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection," 2021, JHEP Reports
  • "Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B," 2022, JHEP Reports
  • "Future treatments for hepatitis delta virus infection," 2020, Liver International
  • "Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life," 2021, Liver International

Collaborations are a prominent element of Patrick Marcellin's research activity. Frequent co-authors include:

  • María Buti (18 joint publications)
  • Anuj Gaggar (12 joint publications)
  • Edward Gane (11 joint publications)
  • Vithika Suri (11 joint publications)
  • Harry L.A. Janssen (10 joint publications)

Best Publications

  • Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

    Hadziyannis Sj;Sette H;Morgan Tr;Balan

  • Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

    Thierry Poynard;Patrick Marcellin;Samuel S Lee;Christian Niederau

  • Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

    Ira M. Jacobson;John G. McHutchison;Geoffrey Dusheiko;Adrian M. Di Bisceglie

  • Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

    Bruce R. Bacon;Stuart C. Gordon;Eric Lawitz;Patrick Marcellin

  • Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.

    Marianne Ziol;Adriana Handra-Luca;Adrien Kettaneh;Christos Christidis

  • Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

    Nezam Afdhal;Stefan Zeuzem;Paul Kwo;Mario Chojkier

  • Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

    Patrick Marcellin;Ting Tsung Chang;Seng Gee Lim;Myron J. Tong

  • Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

    Patrick Marcellin;Edward J Gane;Maria Buti;Nezam H Afdhal

  • Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

    George K.K. Lau;Teerha Piratvisuth;Kang Xian Luo;Patrick Marcellin

  • Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

    Patrick Marcellin;George K.K. Lau;Ferruccio Bonino;Patrizia Farci

  • Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B

    Patrick Marcellin;E Jenny Heathcote;Maria Buti;Ed Gane

  • Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

    Stephanos J. Hadziyannis;Nicolaos C. Tassopoulos;E. Jenny Heathcote;Ting-Tsung Chang

  • Persistence of cccDNA During the Natural History of Chronic Hepatitis B and Decline During Adefovir Dipivoxil Therapy

    Bettina Werle-Lapostolle;Scott Bowden;Stephen Locarnini;Karsten Wursthorn;Karsten Wursthorn

  • Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

    Stephanos J. Hadziyannis;Nicolaos C. Tassopoulos;E. Jenny Heathcote;Ting–Tsung Chang

  • Controlled Attenuation Parameter (CAP): A Novel VCTE™ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes

    Magali Sasso;Michel Beaugrand;Victor de Ledinghen;Catherine Douvin

  • Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

    Thomas Karlas;David Petroff;Magali Sasso;Jian Gao Fan

  • Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B

    Stephanos J. Hadziyannis;Nicolaos C. Tassopoulos;E. Jenny Heathcote;Ting-Tsung Chang

  • Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon-α Therapy

    Patrick Marcellin;Nathalie Boyer;Anne Gervais;Michele Martinot

  • Insulin Resistance in Chronic Hepatitis C: Association With Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis

    Rami Moucari;Tarik Asselah;Dominique Cazals–Hatem;Hélène Voitot

  • Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

    Thierry Poynard;Patrick Marcellin;Samuel S. Lee;Christian Niederau

Frequent Co-Authors

Nathalie Boyer
Nathalie Boyer Université Paris Cité
Tarik Asselah
Tarik Asselah Université Paris Cité
Dominique Valla
Dominique Valla Université Paris Cité
Claude Degott
Claude Degott Beaujon Hospital
Jean-Pierre Benhamou
Jean-Pierre Benhamou Grenoble Alpes University
Marc Bourlière
Marc Bourlière Hôpital Saint Joseph
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Maria Buti
Maria Buti Instituto de Salud Carlos III

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA doesn't just mean becoming a doctor. There are numerous related online degrees and flexible career pathways in healthcare. Many students consider online bsn programs for non nurses as a stepping stone to enter the nursing field, offering a direct path for those with bachelor’s degrees in other disciplines.

For those interested in healthcare administration, accelerated healthcare administration degree programs can fast-track your entry into management roles within hospitals and other medical organizations. If you’re looking for practical options without sit-down entrance exams, several schools offer lpn to rn programs without teas test, making career advancement in nursing more accessible.

Additionally, the growing field of health information management opens doors for those not involved in direct patient care. Accredited medical billing and coding schools online with financial aid can help launch a flexible, in-demand career. Each of these online pathways meets different interests and needs, supporting a wide variety of healthcare careers.

Best Scientists Citing Patrick Marcellin

Trending Scientists